Cara Therapeutics Incorporated (NASDAQ:CARA) Can’t Be Less Risky. Short Interest Decreased

September 17, 2017 - By Winifred Garcia

 Cara Therapeutics Incorporated (NASDAQ:CARA) Can't Be Less Risky. Short Interest Decreased

Investors sentiment decreased to 1.26 in 2016 Q4. Its down 0.57, from 1.83 in 2016Q3. It is negative, as 12 investors sold Cara Therapeutics Inc shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 12.12 million shares or 4.42% more from 11.60 million shares in 2016Q3 were reported.
Bridgeway Mgmt accumulated 143,444 shares. Pennsylvania-based Vanguard Grp Inc Inc has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Moreover, Nationwide Fund has 0% invested in Cara Therapeutics Inc (NASDAQ:CARA) for 20,105 shares. Citigroup accumulated 512 shares. Natl Bank Of America Corp De holds 0% or 17,913 shares. 267,535 were accumulated by Tiaa Cref Invest Management Ltd Liability Co. Eam Lc owns 239,734 shares. Legal General Group Inc Public Limited Company accumulated 0% or 6,723 shares. Pnc Financial Svcs Grp has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Tiedemann Wealth Mgmt Ltd Liability holds 0.02% in Cara Therapeutics Inc (NASDAQ:CARA) or 19,925 shares. Creative Planning accumulated 0% or 13,125 shares. Alphamark Advisors Ltd Com invested in 0.01% or 1,440 shares. Grt Cap Prtn Ltd Liability Corp has invested 0.23% in Cara Therapeutics Inc (NASDAQ:CARA). Fmr Llc has 0% invested in Cara Therapeutics Inc (NASDAQ:CARA). 754,488 are owned by Blackrock Institutional Trust Na.

Since March 31, 2017, it had 1 buy, and 0 sales for $9.10 million activity. RHO Ventures VI LP also bought $9.10 million worth of Cara Therapeutics Inc (NASDAQ:CARA) on Friday, March 31.

The stock of Cara Therapeutics Incorporated (NASDAQ:CARA) registered a decrease of 2.32% in short interest. CARA’s total short interest was 9.08M shares in September as published by FINRA. Its down 2.32% from 9.30M shares, reported previously. With 940,700 shares average volume, it will take short sellers 10 days to cover their CARA’s short positions. The short interest to Cara Therapeutics Incorporated’s float is 39.72%.

The stock increased 3.47% or $0.46 on September 15, reaching $13.73. About 1.38 million shares traded or 24.32% up from the average. Cara Therapeutics Inc (NASDAQ:CARA) has risen 206.00% since September 17, 2016 and is uptrending. It has outperformed by 189.30% the S&P500.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $447.34 million. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It currently has negative earnings. It is developing a class of product candidates that target the body’s peripheral nervous system.

Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage

Among 9 analysts covering Cara Therapeutics (NASDAQ:CARA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Cara Therapeutics had 20 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Friday, August 4 by Piper Jaffray. The rating was initiated by Cantor Fitzgerald on Wednesday, November 4 with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, June 22 report. The stock of Cara Therapeutics Inc (NASDAQ:CARA) has “Buy” rating given on Friday, August 4 by Canaccord Genuity. The firm has “Buy” rating given on Friday, June 30 by Canaccord Genuity. On Friday, June 30 the stock rating was maintained by H.C. Wainwright with “Buy”. Janney Capital downgraded the shares of CARA in report on Friday, June 30 to “Neutral” rating. Scotia Capital maintained Cara Therapeutics Inc (NASDAQ:CARA) on Thursday, November 24 with “Outperform” rating. The firm earned “Buy” rating on Friday, July 24 by Needham. On Thursday, October 13 the stock rating was initiated by H.C. Wainwright with “Buy”.

More important recent Cara Therapeutics Inc (NASDAQ:CARA) news were published by: Fool.com which released: “Big Investors Are Buying Cara Therapeutics Stock. Should You?” on August 31, 2017, also Nasdaq.com published article titled: “Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)”, Fool.com published: “Here’s Why Cara Therapeutics Rose 9.6% in August” on September 07, 2017. More interesting news about Cara Therapeutics Inc (NASDAQ:CARA) was released by: Fool.com and their article: “Here’s Why the Best Is Yet to Come for Cara Therapeutics, Inc.” with publication date: September 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.